Jason Ken Hou, MD
Baylor College of Medicine
Houston, TX

Dr. Jason Hou is an Assistant Professor of Medicine at Baylor College of Medicine (BCM) in Houston, TX. He attended medical school at the Feinberg School of Medicine at Northwestern University and served as resident, chief medical resident, and gastroenterology fellow at BCM. Dr. Hou has additional inflammatory bowel disease (IBD) training through a visiting fellowship at the University of California San Francisco sponsored through the Crohn’s and Colitis Foundation. Dr. Hou is currently director of IBD Research at BCM, Medical Director of IBD at the Michael E. DeBakey VA Medical Center, and Program Director of the Gastroenterology and Hepatology Fellowship at BCM. He is a funded health-services investigator in IBD through institutional, national society, and federal funding mechanisms. His research interests are in diet in IBD, IBD-associated colorectal cancer, and improvement in the quality of care delivery for IBD patients.

 K08 PA13-180 (Hou) 8/1/2015-7/31/2020 AHRQ $766,800 Patient-Centered Comparative Effectiveness of Colorectal Cancer Surveillance in IBD This project compares strategies using colonoscopy to reduce or prevent colorectal cancer among patients with IBD and investigates how patients’ past experiences with colonoscopy influence their decision to have future colonoscopies. Role: Principal Investigator

 2015 Career Development Award (Hou) 8/1/215-7/31/2018 Crohn’s and Colitis Foundation of America $51,058 Patient Centered Comparative Effectiveness of Colorectal Cancer Surveillance in IBD The aim of this study is to identify patient perceptions of colonoscopy and explore the association of surveillance colonoscopy and stage of colon cancer among patients with IBD. Role: Principal Investigator

 U01DK062431 (Brant) NIH/NIDDK $262,158 IBD Gene Mapping by Clinical and Population Subset The major goals of this project are to facilitate more comprehensive IBD gene discovery and evaluation in the African American population and characterize the epigenome relevant to IBD and evaluate the most provocative non-coding SNPs across populations that map to potential TF binding sites for altering genomic function. Role: Site Principal Investigator

 Clinical Trial Grant (Hou) Shield A PHASE 3B, RANDOMIZED, CONTROLLED, MULTICENTRE STUDY WITH ORAL FERRIC MALTOL (FERACCRU) OR INTRAVENOUS IRON (FERRIC CARBOXY MALTOSE; FCM), FOR THE TREATMENT OF IRON DEFICIENCY ANAEMIA IN SUBJECTS WITH INFLAMMATORY BOWEL DISEASE Phase III trial of feraccru for iron deficiency in IBD Role: Site Principal Investigator

 Clinical Trial Grant (Hou) Abbvie “PROTOCOL P11-282 - A LONG-TERM NON-INTERVENTIONAL REGISTRY TO ASSESS SAFETY AND EFFECTIVENESS OF HUMIRA® (ADALIMUMAB) IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (UC)” Registry of adaliumuab for UC Role: Site Principal Investigator

 Clinical Trial Grant (Hou) Genentech “A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ETROLIZUMAB AS AN INDUCTION AND MAINTENANCE TREATMENT FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE (GA29144) Phase III Trial of Etrolizuamb in Crohn’s disease Role: Site Principal Investigator

 Clinical Trial Grant (Hou) Pfizer, Inc “A MULTI-CENTER, OPEN-LABEL STUDY OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS” Phase III Trial of Tofacitinib in ulcerative colitis Role: Site Principal Investigator

 Clinical Trial Grant (Hou) Pfizer, Inc “A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS AN INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS” Phase III Trial of Tofacitinib in ulcerative colitis Role: Site Principal Investigator

 Clinical Trial Grant (Hou) Pfizer, Inc “A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS A MAINTENANCE THERAPY IN SUBJECTS WITH ULCERATIVE COLITIS (A3921096)” Phase III Trial of Tofacitinib in ulcerative colitis Role: Site Principal Investigator

    Webcasts

    Impact of IBD on Healthcare Systems

    Gary Lichtenstein, MD ; David Rubin, MD ; Bruce Sands, MD ; Brennan Spiegel, MD ; Douglas Wolf, MD

    Didactic Lecture

    view details >

    eMonograph

    GI Alliance Payer Summit

    view details >

    Clinical and Managed Care Perspectives in Inflammatory Bowel Disease: Closing the Gap

    view details >

    Addressing Health Outcomes and Rising Costs in the Management of Inflammatory Bowel Disease

    view details >

    The Guide to Guidelines in IBD: Interpretation and Appropriate Use in Clinical Practice

    view details >

    INFORM UC: An Update on Contemporary Management of UC

    view details >

    Breaking The Barriers: Improving Access to Biologic Therapies in IBD

    view details >

    IBD Management: State of the Art in 2018

    view details >

    Improving IBD Care A Personalized Approach to Management

    view details >

    Expert Perspectives in the Management of Inflammatory Bowel Disease (IBD): A Review of Recent Advances

    view details >

    Advances in IBD

    view details >

    Optimizing the Management of Inflammatory Bowel Disease

    view details >

    Webcasts

    Impact of IBD on Healthcare Systems

    Gary Lichtenstein, MD ; David Rubin, MD ; Bruce Sands, MD ; Brennan Spiegel, MD ; Douglas Wolf, MD

    Didactic Lecture

    view details >

    Dinner Meetings

    Content available soon

    Audiocasts

    Content available soon!

    Content available soon!

    © Copyright 2013-2024 GI Health Foundation. All rights reserved.
    This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.